GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jupiter Neurosciences JUNS · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.20

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jupiter Neurosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Jupiter Neurosciences is based in Jupiter, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker JUNS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $21,796 and a net loss of $8.6m. At that date it held total assets of $5.6m and shareholders' equity of −$1.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Dec 2024
Employees
4
Head office
1001 NORTH US HWY 1, JUPITER, FL, 33477
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Christer RosenChairman of the Board, Chief Executive Officer, Co-Founder, since 2016$697,627
  • Ms. Alison SilvaPresident, Chief Business Officer, Director, since 2018
  • Mr. Alexander RosenCo-Founder, Chief Administrative Officer
  • Dr. Marshall HaywardCo-Founder, Chief Scientific Officer, Director, since 2016$507,145
  • Mr. Saleem ElmasriChief Financial Officer
  • Ms. Allison BradyDirector$21,530
  • Mr. Nicholas HemmerlyDirector$24,343
  • Ms. Julie KampfDirector$22,311
  • Mr. Holger WeisDirector$22,780

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Jupiter Neurosciences has a resveratrol platform targeting neuro-inflammation treatment.
  • JOTROL, a micellar non-aqueous solution, is delivered in soft gel capsules containing 100 mg resveratrol.
  • The company holds a worldwide license from Aquanova AG for JOTROL development and distribution.

Weaknesses

  • The company employs only 4 full-time employees in Palm Beach Gardens, Florida.
  • Jupiter Neurosciences has a clinical stage research and development focus with no commercial products yet.
  • The firm's IPO occurred on 3 December 2024, indicating early-stage operations.

Opportunities

  • JOTROL targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS rare diseases.
  • The product has potential indications for Parkinson's Disease and early Alzheimer’s disease.
  • Jupiter Neurosciences has project numbers JNS101 to JNS115 for different indications.

Threats

  • The company's clinical stage development faces regulatory approval risks for JOTROL.
  • Jupiter Neurosciences has limited resources with only 4 employees and a recent IPO.
  • The pharmaceutical industry has high competition for neuro-inflammation treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.